FDA grants pri­or­i­ty re­view for Rubra­ca; Arpeg­gio snags $3.2M in seed fi­nanc­ing

→ Months af­ter the UK’s cost-ef­fec­tive­ness agency NICE had a change of heart on its drug Rubra­ca  — Clo­vis has an­nounced that the FDA grant­ed pri­or­i­ty re­view for its ap­pli­ca­tion to ex­pand the use of the drug to pa­tients with BR­CA1/2-mu­tant re­cur­rent, metasta­t­ic cas­trate-re­sis­tant prostate can­cer. The PDU­FA date is May 15, 2020. Clo­vis’ shares $CLVS rose near­ly 13.5% to $10.10 in Wednes­day morn­ing trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.